Hikma Pharmaceuticals Plc · LSE:HIK

Hikma Pharmaceuticals — 38th Annual JP Morgan Healthcare Conference (January 2020)

20 slides from Hikma Pharmaceuticals's conference presentation, January 2020

  1. Slide 1: Better health. Within reach. Every day.

    Better health. Within reach. Every day. Hikma Pharmaceuticals PLC January 2020

  2. Slide 2: A unique and well-diversified business model

    A unique and well-diversified business model Our markets Our operations Injectables 1H19 segmental revenue 5% $428m Europe 1H19 Group revenue & rest of the c.900 world employees Generics 66% 1H19 segmental revenue 1H19 Group USA revenue c.1,900 $368m 29% employees 1H19 Group MENA revenue Branded c.5

  3. Slide 3: Delivering sustainable growth

    Delivering sustainable growth Hikma Pharmaceuticals PLC 3

  4. Slide 4: Injectables

    Injectables

  5. Slide 5: Injectables overview and financial performance

    Injectables overview Injectables financial performance ($ million) Top 3 3 core $900 100% generic injectables geographies $800 manufacturer in 80% $700 the US $600 60% $500 $400 5 1 billion units $300 40% manufacturing of annual sites around the injectables $200 20% world manufacturing $100 capacity

  6. Slide 6: Resilient portfolio and new launches are offsetting headwinds to drive growth

    Resilient portfolio and new launches are offsetting headwinds to drive growth US Injectables core revenue by product type Partnering with Civica Rx (million) $350 5-year agreement to manufacture and Total1 supply Civica’s growing membership of $300 US health systems (1,100+ hospitals) $250 Base port

  7. Slide 7: Developing a pipeline of differentiated products to drive future growth

    Developing a pipeline of differentiated products to drive future growth Ongoing expansion of our US Injectables portfolio1 US Injectables pipeline of 125 products3 Complex products Other 111 products across c.14 therapeutic categories2 111 Projects 97 69 89 Development 72 67 55 14 59 Submissions 56

  8. Slide 8: Investing in our portfolio and manufacturing capabilities for MENA and Europe

    Investing in our portfolio and manufacturing capabilities for MENA and Europe Herzuma® Truxima® Remsima® $180m market 1 •Biosimilar to Herceptin ® $100m •Expect to launch in market 1 4 markets by end of 2020 $45m market1 •Biosimilar to Rituxan ® •Launched in 1 market to date. Additional markets in 2

  9. Slide 9: Generics

    7) 2 ta © | ® jo)

  10. Slide 10: Generics overview and financial performance

    Generics overview Generics financial performance ($ million) State of Capabilities $800 100% the art in orals, liquids, nasal $700 sprays, respiratory, manufacturing 80% high-containment facility in and controlled $600 Columbus, Ohio substances $500 60% $400 >80 Over 1,000 $300 40% products employee

  11. Slide 11: Our differentiated product portfolio and enhanced commercial capabilities are delivering growth

    Our differentiated product portfolio and enhanced commercial capabilities are delivering growth Volumes in US non-injectables market are stable Generics portfolio by number of generic competitors1 (eaches) 6% 15% 24% ≤2 4% 3-5 6-8 2% 33% ≥9 28% 0% 2015 2016 2017 2018 2019 YTD 1 Price erosion appears

  12. Slide 12: Developing a pipeline of complex products to drive future growth

    Developing a pipeline of complex products to drive future growth Pipeline by dosage form Our disclosed Generics Paragraph IV pipeline (as at July 2019) Current Product PIV status US market size ($m)1 6% Afinitor® Settled 825 Novartis 6% Fetzima® Active litigation 99 Allergan 38% Tarceva® 14% Genente

  13. Slide 13: Branded

    Branded

  14. Slide 14: Branded overview and financial performance

    Branded overview Branded financial performance in constant currency1 ($ millions) 5th largest Manufacturing 100% pharma facilities in $800 company in 7 countries 80% MENA $600 60% $400 ~2,000 sales Presence in over 40% representatives 30 markets $200 20% $0 0% 2014 2015 2016 2017 2018 Revenue Core o

  15. Slide 15: Launching differentiated products and adding new partnerships

    Launching differentiated products and adding new partnerships 1H19 key launches in core markets 2019 partnerships Exclusive license agreement to commercialise cariprazine, a novel antipsychotic, in certain MENA markets License agreement for Bilastine orally disintegrating tablet and Algeria Egypt Sa

  16. Slide 16: Group

    Group

  17. Slide 17: Delivering sustainable growth

    Delivering sustainable growth Deliver more • Driving strong organic growth from a strong • Achieving cost savings and efficiencies foundation • Leveraging our high-quality operations Inspire and • Strengthening our commercial teams and Group functions Better health. enable our • Focusing on initiati

  18. Slide 18: Appendix

    Appendix

  19. Slide 19: 2019 guidance

    2019 guidance Injectables Generics Branded ● Revenue: ● Revenue: ● Revenue growth in constant $870 million to $900 million $690 million to $720 million currency: ● Core operating margin: ● Core operating margin: mid-single digits 36% to 38% 16% to 18% Net finance expense Capital expenditure Tax ● Ne

  20. Slide 20: Better health. Within Reach. Everyday.

    Better health. Within Reach. Everyday. Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals — 38th Annual JP Morgan Healthcare Conference (January 2020) on 6ix